Recently, a randomized phase II clinical study explored the effect of osimertinib in combination with carboplatin-pemetrexed compared to osimertinib monotherapy among EGFR-mutated NSCLC patients withT790M in the second-line setting. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.